
  
    
      
        Background_NNP
        In_IN 1990_CD the_DT National_NNP Institutes_NNPS of_IN Health_NNP Consensus_NNP
        Development_NNP Conference_NNP [_NN 1_CD ]_NN concluded_VBD that_DT breast_NN
        conserving_VBG surgery_NN (_( BCS_NNP )_) followed_VBN by_IN radiation_NN is_VBZ an_DT
        appropriate_JJ method_NN of_IN primary_JJ treatment_NN for_IN the_DT majority_NN of_IN
        women_NNS with_IN early_JJ stage_NN breast_NN cancer_NN (_( AJCC_NNP stages_NNS [_NN 2_CD ]_NN I_PRP ,_,
        IIA_NNP ,_, and_CC IIB_NNP )_) ._. Numerous_JJ clinical_JJ studies_NNS have_VBP shown_VBN that_DT
        survival_NN after_IN BCS_NNP followed_VBN by_IN radiation_NN therapy_NN is_VBZ
        equivalent_JJ to_TO survival_NN following_VBG mastectomy_NN for_IN women_NNS in_IN
        these_DT stages_NNS [_NN 3_CD 4_CD 5_CD ]_NN ._. Some_DT absolute_JJ indicators_NNS for_IN
        mastectomy_NN remain_VB [_NN 6_CD 7_CD ]_NN ,_, in_IN particular_JJ widespread_JJ
        malignant-type_JJ microcalcifications_NNS ,_, previous_JJ radiotherapy_NN ,_,
        and_CC a_DT relation_NN of_IN tumor_NN size_NN to_TO breast_NN size_NN that_WDT would_MD not_RB
        allow_VB a_DT cosmetically_RB satisfactory_JJ result_NN ._. Although_IN there_EX
        has_VBZ been_VBN an_DT increase_NN in_IN the_DT use_NN of_IN BCS_NNP since_IN the_DT early_JJ
        1990_CD s_VBZ ,_, an_DT apparent_JJ under-utilization_JJ of_IN BCS_NNP among_IN women_NNS for_IN
        whom_WP such_JJ treatment_NN was_VBD not_RB contraindicated_JJ has_VBZ been_VBN
        documented_VBN [_NN 8_CD ]_NN ._. Geographic_NNP location_NN ,_, type_NN of_IN hospital_NN
        and_CC health_NN plan_NN ,_, and_CC personal_JJ preferences_NNS have_VBP been_VBN
        investigated_VBN as_IN possible_JJ factors_NNS to_TO explain_VB the_DT continued_VBN
        use_NN of_IN mastectomy_NN [_NN 9_CD 10_CD 11_CD 12_CD ]_NN ._. Comorbidity_NNP [_NN 13_CD ]_NN has_VBZ
        been_VBN found_VBN to_TO be_VB an_DT important_JJ predictor_NN among_IN older_JJR
        women_NNS ._.
        The_DT Surveillance_NNP ,_, Epidemiology_NNP and_CC End_NN Results_NNS (_( SEER_NNP )_)
        cancer_NN registries_NNS do_VBP not_RB collect_VB sufficient_JJ detail_NN to_TO
        examine_VB some_DT of_IN these_DT issues_NNS and_CC medical_JJ records_NNS reviews_NNS
        are_VBP time_NN consuming_NN ._. Insurance_NN claims_VBZ data_NNS are_VBP a_DT
        cost-effective_JJ alternative_NN ;_: they_PRP have_VBP already_RB been_VBN
        collected_VBN and_CC put_VBD into_IN an_DT electronic_JJ format_NN by_IN the_DT
        insurance_NN carriers_NNS ._. They_PRP cover_VBP large_JJ segments_NNS of_IN the_DT
        population_NN ,_, allow_VB follow-up_JJ ,_, use_NN standardized_JJ codes_NNS [_NN 14_CD 15_CD
        ]_NN ,_, and_CC do_VBP not_RB rely_VB on_IN subject_JJ recall_NN ._. In_IN cancer_NN research_NN ,_,
        insurance_NN claims_VBZ data_NNS have_VBP been_VBN used_VBN to_TO estimate_VB the_DT
        effectiveness_NN of_IN cervical_JJ cancer_NN screening_NN [_NN 16_CD ]_NN ,_, to_TO
        assess_VB the_DT role_NN of_IN screening_NN practices_NNS in_IN the_DT incidence_NN of_IN
        prostate_NN cancer_NN [_NN 17_CD ]_NN ,_, and_CC to_TO estimate_VB mammography_NN
        participation_NN [_NN 18_CD ]_NN ._. Medicare_NNP enrollees_NNS in_IN Seattle_NNP and_CC
        San_NNP Francisco_NNP who_WP received_VBD care_NN from_IN a_DT Health_NNP Maintenance_NNP
        Organization_NNP (_( HMO_NNP )_) were_VBD found_VBN to_TO receive_VB more_JJR BCS_NNP than_IN
        women_NNS in_IN Fee-_NNP For-_NNP Service_NNP (_( FFS_NNP )_) plans_NNS [_NN 19_CD ]_NN ._. Whereas_IN a_DT
        Medicare_NNP /_NN SEER_NNP registry_NN linked_VBD data_NNS set_VBN has_VBZ been_VBN used_VBN
        extensively_RB to_TO examine_VB treatment_NN and_CC screening_NN issues_NNS in_IN
        individuals_NNS 65_CD years_NNS and_CC older_JJR [_NN 20_CD ]_NN ,_, linking_VBG of_IN
        insurance_NN claims_VBZ data_NNS from_IN private_JJ health_NN plans_NNS in_IN younger_JJR
        populations_NNS has_VBZ been_VBN more_RBR difficult_JJ because_IN of_IN the_DT large_JJ
        number_NN of_IN health_NN plans_NNS in_IN most_JJS geographic_JJ areas_NNS ._. However_RB ,_,
        Hawaii_NNP provides_VBZ unique_JJ opportunities_NNS for_IN insurance_NN claims_NNS
        research_NN because_IN the_DT majority_NN of_IN medical_JJ care_NN is_VBZ received_VBN
        within_IN the_DT state_NN and_CC more_JJR than_IN 90_CD %_NN of_IN the_DT population_NN [_NN 21_CD ]_NN
        are_VBP covered_VBN by_IN a_DT limited_JJ number_NN of_IN health_NN plans_NNS ._. As_IN a_DT pilot_NN
        project_NN ,_, we_PRP were_VBD able_JJ to_TO link_VB data_NNS from_IN the_DT Hawaii_NNP Tumor_NNP
        Registry_NNP and_CC from_IN a_DT health_NN plan_NN in_IN Hawaii_NNP ._. The_DT objectives_NNS
        of_IN this_DT analysis_NN were_VBD to_TO describe_VB breast_NN cancer_NN treatment_NN
        and_CC comorbid_NN conditions_NNS using_VBG the_DT insurance_NN claims_VBZ data_NNS and_CC
        to_TO examine_VB possible_JJ determinants_NNS of_IN BCS_NNP 
        vs_NNS ._. mastectomy_NN for_IN breast_NN cancer_NN
        patients_NNS with_IN stage_NN I_PRP and_CC II_NNP disease_NN ._.
      
      
        Methods_NNP
        
          Data_NNP Sources_NNS
          The_DT HTR_NNP has_VBZ maintained_VBN a_DT database_NN of_IN all_DT cases_NNS of_IN
          cancer_NN diagnosed_VBN in_IN the_DT State_NNP of_IN Hawaii_NNP since_IN 1960_CD and_CC
          became_VBD part_NN of_IN the_DT SEER_NNP program_NN in_IN 1973_CD ._. The_DT HTR_NNP record_NN
          contains_VBZ demographic_JJ characteristics_NNS such_JJ as_IN age_NN ,_,
          ethnicity_NN ,_, marital_JJ status_NN ,_, island_NN of_IN residence_NN ,_, as_RB well_RB
          as_IN information_NN on_IN tumor_NN size_NN ,_, extent_NN of_IN disease_NN ,_, lymph_NN
          node_NN involvement_NN ,_, and_CC tumor_NN grade_NN ._. From_IN medical_JJ records_NNS
          in_IN hospitals_NNS and_CC physicians_NNS '_POS offices_NNS ,_, information_NN is_VBZ
          collected_VBN on_IN the_DT initial_JJ course_NN (_( six_CD months_NNS in_IN the_DT Hawaii_NNP
          Tumor_NNP Registry_NNP )_) of_IN cancer-directed_JJ treatment_NN following_VBG
          diagnosis_NN ._. Quality_JJ control_NN reviews_NNS have_VBP shown_VBN that_IN
          case-ascertainment_JJ through_IN HTR_NNP has_VBZ been_VBN virtually_RB
          complete_JJ [_NN 22_CD ]_NN ._. Over_IN 99_CD %_NN of_IN cancer_NN cases_NNS reported_VBD to_TO
          the_DT registry_NN are_VBP histologically_RB confirmed_VBN ._. The_DT HTR_NNP also_RB
          maintains_VBZ a_DT link_NN with_IN Hawaii_NNP Department_NNP of_IN Health_NNP ,_, which_WDT
          allows_VBZ for_IN death_NN information_NN to_TO be_VB captured_VBN in_IN the_DT HTR_NNP
          database_NN ._.
        
        
          Linking_VBG
          The_DT insurance_NN claims_NNS for_IN this_DT study_NN were_VBD obtained_VBN from_IN
          a_DT local_JJ insurer_NN who_WP was_VBD a_DT party_NN to_TO the_DT memorandum_NN of_IN
          agreement_NN ._. The_DT linked_VBN data_NN set_VBN contained_VBD cancer_NN cases_NNS
          diagnosed_VBN from_IN 1995_CD through_IN 1998_CD ._. During_IN the_DT linking_VBG
          process_NN ,_, a_DT list_NN of_IN health_NN plan_NN members_NNS who_WP had_VBD at_IN least_JJS
          two_CD cancer_NN diagnostic_JJ codes_NNS in_IN their_PRP$ claims_NNS history_NN were_VBD
          matched_VBN against_IN the_DT HTR_NNP using_VBG a_DT probabilistic_JJ method_NN ._. For_IN
          each_DT matched_VBN record_NN ,_, the_DT health_NN plan_NN furnished_VBN all_DT claims_NNS
          data_NN for_IN that_DT period_NN ._. They_PRP also_RB indicated_VBD whether_IN the_DT
          individual_NN was_VBD enrolled_VBN in_IN a_DT Fee-_NNP For-_NNP Service_NNP (_( FFS_NNP )_) or_CC a_DT
          capitated_JJ (_( HMO_NNP )_) plan_NN ,_, a_DT choice_NN provided_VBN by_IN the_DT insurer_NN ._.
          However_RB ,_, the_DT majority_NN of_IN linked_VBN cancer_NN cases_NNS belonged_VBD to_TO
          the_DT FFS_NNP plan_NN and_CC the_DT HMO_NNP plan_NN provided_VBN by_IN this_DT insurer_NN
          differs_VBZ considerably_RB from_IN a_DT typical_JJ HMO_NNP ._. Individuals_NNS aged_VBN
          65_CD years_NNS and_CC older_JJR were_VBD included_VBN only_RB if_IN they_PRP were_VBD still_RB
          working_VBG and_CC had_VBD primary_JJ coverage_NN through_IN the_DT health_NN plan_NN
          or_CC if_IN they_PRP were_VBD covered_VBN under_IN Medicare_NNP but_CC also_RB had_VBD
          secondary_JJ coverage_NN through_IN the_DT health_NN plan_NN ._. The_DT dataset_NN
          furnished_VBN by_IN the_DT health_NN insurer_NN contained_VBD all_DT claims_NNS
          processed_VBN for_IN cancer_NN patients_NNS in_IN this_DT study_NN ._. The_DT data_NNS
          elements_NNS included_VBD :_: date_NN of_IN service_NN ,_, International_NNP
          Classification_NNP of_IN Disease_NNP ,_, version_NN 9_CD (_( ICD-_NNP 9_CD )_) diagnosis_NN
          codes_NNS [_NN 14_CD ]_NN ,_, Current_NNP Procedural_NNP Terminology_NNP (_( CPT_NNP )_) codes_NNS
          [_NN 15_CD ]_NN ,_, and_CC the_DT provider_NN specialty_NN code_NN ._. The_DT dataset_NN
          contained_VBD claims_NNS for_IN services_NNS from_IN physicians_NNS ,_,
          laboratories_NNS ,_, freestanding_VBG facilities_NNS ,_, as_RB well_RB as_IN
          outpatient_NN services_NNS provided_VBN by_IN hospital_NN facilities_NNS ._.
        
        
          Data_NNP set_VBD
          Breast_NNP cancer_NN cases_NNS accounted_VBD for_IN 16_CD ._. 6_CD %_NN of_IN all_DT cancer_NN
          cases_NNS recorded_VBN in_IN the_DT HTR_NNP during_IN the_DT period_NN from_IN 1995_CD to_TO
          1998_CD ._. In_IN the_DT linked_VBN dataset_NN ,_, 27_CD ._. 7_CD %_NN of_IN the_DT cases_NNS were_VBD
          breast_NN cancer_NN cases_NNS ._. Using_VBG the_DT ICD-_NNP 9_CD -_: CM_NNP code_NN range_NN [_NN 14_CD ]_NN
          for_IN breast_NN cancer_NN (_( 174_CD ._. 0_CD to_TO 174_CD ._. 9_CD )_) ,_, we_PRP identified_VBD 1_CD ,_, 377_CD
          female_JJ breast_NN cancer_NN cases_NNS ._. We_PRP then_RB excluded_VBD 265_CD cases_NNS
          diagnosed_VBN after_IN June_NNP 30_CD ,_, 1998_CD because_IN we_PRP would_MD not_RB have_VB a_DT
          complete_JJ history_NN of_IN claims_NNS data_NNS covering_VBG at_IN least_JJS six_CD
          months_NNS of_IN treatment_NN ._. We_PRP also_RB identified_VBD 30_CD women_NNS who_WP had_VBD
          been_VBN recorded_VBN twice_RB in_IN the_DT linked_VBN dataset_NN because_IN breast_NN
          cancer_NN was_VBD diagnosed_VBN in_IN both_DT breasts_NNS ,_, as_IN identified_VBN by_IN
          the_DT laterality_NN codes_NNS ._. For_IN 24_CD women_NNS ,_, the_DT diagnosis_NN date_NN
          was_VBD identical_JJ ,_, in_IN which_WDT case_NN we_PRP considered_VBD the_DT two_CD
          diagnoses_NNS as_IN one_CD case_NN ._. For_IN the_DT six_CD cases_NNS with_IN different_JJ
          diagnoses_NNS dates_NNS ,_, we_PRP retained_VBD both_DT records_NNS because_IN there_EX
          was_VBD a_DT separate_JJ completed_VBN course_NN of_IN treatment_NN for_IN the_DT
          cancer_NN in_IN each_DT breast_NN ._. We_PRP eliminated_VBD one_CD case_NN that_WDT was_VBD in_IN
          the_DT linked_VBN dataset_NN and_CC had_VBD inpatient_NN data_NNS but_CC no_DT
          outpatient_NN data_NN ,_, resulting_VBG in_IN a_DT dataset_NN containing_VBG 1_CD ,_, 088_CD
          breast_NN cancer_NN cases_NNS ._.
        
        
          Staging_NNP
          We_PRP used_VBD the_DT HTR_NNP information_NN in_IN the_DT Extent_NNP of_IN Disease_NNP
          (_( EOD-_NNP 10_CD )_) field_NN [_NN 23_CD ]_NN to_TO determine_VB the_DT American_NNP Joint_NNP
          Committee_NNP on_IN Cancer_NNP (_( AJCC_NNP )_) TNM_NNP stage_NN [_NN 2_CD ]_NN ,_, where_WRB T_NN
          represents_VBZ the_DT primary_JJ tumor_NN size_NN ,_, N_NNP refers_VBZ to_TO lymph_NN node_NN
          involvement_NN ,_, and_CC M_NNP refers_VBZ to_TO presence_NN of_IN metastases_NNS ._. In_IN
          cases_NNS where_WRB the_DT tumor_NN size_NN was_VBD unknown_JJ ,_, we_PRP assigned_VBN a_DT
          stage_NN only_RB if_IN the_DT size_NN was_VBD not_RB a_DT determinant_NN in_IN the_DT TNM_NNP
          grouping_VBG ._. If_IN the_DT extension_NN was_VBD unknown_JJ ,_, we_PRP equated_VBN it_PRP to_TO
          extension_NN 10_CD (_( confinement_NN to_TO breast_NN tissue_NN and_CC fat_JJ )_) ._. For_IN
          the_DT small_JJ number_NN of_IN cases_NNS (_( N_NNP =_SYM 8_CD )_) for_IN whom_WP lymph_NN node_NN
          involvement_NN code_NN was_VBD unknown_JJ ,_, we_PRP considered_VBD this_DT the_DT same_JJ
          as_IN no_DT lymph_NN node_NN involvement_NN because_IN the_DT tumor_NN size_NN was_VBD
          so_RB small_JJ for_IN these_DT cases_NNS that_IN a_DT lymph_NN node_NN dissection_NN was_VBD
          not_RB considered_VBN necessary_JJ at_IN the_DT time_NN of_IN this_DT study_NN ._. The_DT
          results_NNS of_IN the_DT TNM_NNP staging_NN agreed_VBD well_RB with_IN the_DT SEER_NNP
          summary_NN stage_NN codes_NNS ._.
        
        
          Cancer_NN treatment_NN
          We_PRP used_VBD the_DT CPT_NNP codes_NNS [_NN 15_CD ]_NN in_IN the_DT claims_NNS dataset_NN to_TO
          identify_VB the_DT type_NN of_IN surgery_NN performed_VBN ._. For_IN mastectomies_NNS ,_,
          we_PRP included_VBD codes_NNS for_IN simple_JJ and_CC subcutaneous_JJ
          mastectomies_NNS (_( 19180_CD and_CC 19182_CD )_) ,_, radical_JJ mastectomies_NNS
          (_( 19200_CD and_CC 19220_CD )_) and_CC modified_VBN radical_JJ mastectomy_NN
          (_( 19240_CD )_) ._. BCS_NNP was_VBD identified_VBN by_IN the_DT CPT_NNP codes_NNS for_IN partial_JJ
          mastectomies_NNS (_( 19160_CD ,_, 19162_CD )_) ._. We_PRP also_RB included_VBD codes_NNS for_IN
          excision_NN of_IN breast_NN cysts_NNS or_CC lesions_NNS (_( 19120_CD and_CC 19125_CD )_) as_IN
          these_DT codes_NNS meet_VBP the_DT definition_NN of_IN a_DT lumpectomy_NN ,_, although_IN
          we_PRP recognize_VBP that_IN some_DT surgeons_NNS may_MD have_VB billed_VBN these_DT
          codes_NNS for_IN excisional_NN biopsies_NNS as_IN a_DT diagnostic_JJ procedure_NN ._.
          If_IN BCS_NNP was_VBD initially_RB performed_VBN ,_, but_CC followed_VBN by_IN a_DT
          subsequent_JJ mastectomy_NN ,_, the_DT subject_NN was_VBD classified_VBN in_IN the_DT
          mastectomy_NN group_NN ._. This_DT situation_NN would_MD have_VB occurred_VBN when_WRB
          the_DT BCS_NNP code_NN was_VBD actually_RB used_VBN for_IN a_DT diagnostic_JJ biopsy_NN
          and_CC the_DT subsequent_JJ surgical_JJ treatment_NN was_VBD a_DT mastectomy_NN or_CC
          in_IN situations_NNS where_WRB a_DT lumpectomy_NN was_VBD first_RB selected_VBN ,_, but_CC
          a_DT mastectomy_NN became_VBD necessary_JJ because_IN pathological_JJ
          examination_NN revealed_VBD cancerous_JJ cells_NNS in_IN the_DT margins_NNS of_IN
          the_DT excised_VBN tissue_NN ._. CPT_NNP codes_NNS 77261_CD to_TO 77799_CD were_VBD
          selected_VBN to_TO determine_VB whether_IN radiation_NN therapy_NN was_VBD
          received_VBN ._. Several_JJ CPT_NNP codes_NNS and_CC also_RB a_DT number_NN of_IN other_JJ
          codes_NNS used_VBN by_IN the_DT health_NN plan_NN for_IN billing_NN were_VBD considered_VBN
          evidence_NN of_IN chemotherapy_NN treatment_NN ._.
        
        
          Comorbidities_NNP
          Information_NNP on_IN the_DT existence_NN of_IN comorbidities_NNS was_VBD
          extracted_VBN from_IN the_DT claims_NNS data_NN using_VBG the_DT occurrence_NN of_IN
          ICD-_NNP 9_CD codes_NNS associated_VBN with_IN comorbid_NN conditions_NNS included_VBN
          in_IN the_DT Charlson_NNP Index_NNP [_NN 24_CD ]_NN ._. We_PRP also_RB analyzed_VBD data_NNS for_IN
          conditions_NNS that_WDT were_VBD not_RB included_VBN in_IN that_DT index_NN ,_, but_CC
          occurred_VBD at_IN a_DT high_NN enough_JJ frequency_NN to_TO warrant_VB
          examination_NN as_IN possible_JJ comorbidities_NNS ,_, in_IN particular_JJ
          hypertension_NN and_CC lipid_NN disorders_NNS ._. We_PRP included_VBD the_DT
          following_VBG twelve_CD comorbid_NN conditions_NNS into_IN our_PRP$ index_NN :_:
          diabetes_NN with_IN complications_NNS ,_, diabetes_NN w_NN /_NN o_NN complications_NNS ,_,
          hypertension_NN ,_, heart_NN disease_NN ,_, cerebrovascular_NN disease_NN ,_,
          chronic_JJ pulmonary_JJ disease_NN ,_, peripheral_JJ vascular_NN disease_NN ,_,
          kidney_NN disease_NN ,_, liver_NN disease_NN ,_, rheumatological_JJ diseases_NNS ,_,
          hypothyroidism_NN ,_, and_CC lipid_NN metabolism_NN disorders_NNS ._.
          Comorbidities_NNP were_VBD based_VBN on_IN physicians_NNS '_POS claims_NNS with_IN the_DT
          respective_JJ ICD-_NNP 9_CD code_NN [_NN 14_CD ]_NN during_IN the_DT 12_CD -_: months_NNS period_NN
          preceding_VBG the_DT month_NN in_IN which_WDT the_DT cancer_NN was_VBD diagnosed_VBN ._.
          The_DT month_NN of_IN diagnosis_NN was_VBD excluded_VBN to_TO avoid_VB identifying_VBG
          as_IN comorbidities_NNS any_DT complications_NNS or_CC conditions_NNS directly_RB
          resulting_VBG from_IN cancer_NN treatment_NN ._. Laboratory_NNP ,_, radiology_NN ,_,
          and_CC other_JJ diagnostic_JJ services_NNS were_VBD excluded_VBN from_IN the_DT
          comorbidity_NN identification_NN process_NN because_IN tests_NNS may_MD have_VB
          been_VBN done_VBN to_TO rule_VB out_RP the_DT condition_NN ._. Each_DT subject_NN was_VBD
          assigned_VBN a_DT comorbidity_NN score_NN of_IN 0_CD (_( no_DT condition_NN )_) ,_, 1_CD (_( one_CD
          condition_NN )_) ,_, or_CC 2_CD (_( two_CD or_CC more_JJR conditions_NNS )_) ._.
        
        
          Other_JJ variables_NNS
          In_IN addition_NN to_TO stage_VB at_IN diagnosis_NN and_CC size_NN of_IN tumor_NN ,_,
          we_PRP examined_VBD several_JJ other_JJ variables_NNS that_WDT were_VBD possible_JJ
          determinants_NNS in_IN the_DT utilization_NN of_IN BCS_NNP 
          vs_NNS ._. mastectomy_NN in_IN early_JJ stage_NN
          breast_NN cancer_NN ,_, including_VBG age_NN at_IN diagnosis_NN ,_, ethnicity_NN ,_,
          island_NN of_IN residence_NN ,_, and_CC marital_JJ status_NN ._. For_IN ethnicity_NN ,_,
          we_PRP used_VBD the_DT five_CD major_JJ groups_NNS in_IN Hawaii_NNP (_( Japanese_JJ ,_,
          Caucasian_NNP ,_, Hawaiian_JJ ,_, Filipino_NNP ,_, and_CC Chinese_JJ )_) ._. All_DT other_JJ
          ethnicities_NNS were_VBD grouped_VBN into_IN an_DT "_'' Other_JJ "_'' category_NN ._. The_DT
          specific_JJ island_NN of_IN residence_NN was_VBD coded_VBN in_IN the_DT HTR_NNP ,_, but_CC
          since_IN close_JJ to_TO 80_CD %_NN of_IN the_DT population_NN resides_VBZ on_IN Oahu_NNP [_NN 25_CD
          ]_NN ,_, we_PRP classified_VBD residence_NN as_IN either_DT Oahu_NNP or_CC non-_NN Oahu_NNP ._.
          For_IN marital_JJ status_NN ,_, we_PRP grouped_VBN all_DT women_NNS who_WP were_VBD
          identified_VBN as_IN single_JJ ,_, separate_JJ ,_, divorced_VBN or_CC widowed_VBN in_IN
          the_DT unmarried_JJ category_NN ._. Women_NNS under_IN age_NN 50_CD were_VBD
          considered_VBN pre-menopausal_JJ and_CC women_NNS 50_CD years_NNS and_CC older_JJR
          were_VBD classified_VBN as_IN postmenopausal_NN ._. Tumor_NNP grade_NN
          information_NN from_IN the_DT HTR_NNP record_NN was_VBD grouped_VBN into_IN grade_NN I_PRP
          (_( well-differentiated_JJ cells_NNS )_) 
          vs_NNS ._. all_DT other_JJ grades_NNS (_( II_NNP ,_, III_NNP ,_, IV_NNP
          and_CC unknown_JJ )_) ._.
        
        
          Statistical_NNP analysis_NN
          All_DT analyses_NNS were_VBD performed_VBN with_IN SAS_NNP version_NN 8_CD ._. 00_CD for_IN
          Windows_NNP (_( SAS_NNP Institute_NNP ,_, Cary_NNP ,_, NC_NNP )_) ._. Simple_NN Kappa_NNP
          statistics_NNS (_( κ_NN )_) was_VBD calculated_VBN to_TO validate_NN the_DT treatment_NN
          information_NN from_IN the_DT insurance_NN claims_NNS and_CC the_DT HTR_NNP [_NN 26_CD 27_CD
          ]_NN ._. BCS_NNP was_VBD used_VBN as_IN reference_NN group_NN throughout_IN the_DT
          analysis_NN ._. It_PRP was_VBD defined_VBN as_IN the_DT dependent_JJ (_( outcome_NN )_)
          variable_JJ and_CC coded_VBN as_IN a_DT dichotomous_JJ variable_NN ,_, with_IN 1_CD
          indicating_VBG BCS_NNP received_VBD and_CC 0_CD indicating_VBG mastectomy_NN
          received_VBD ._. Age_NNP was_VBD entered_VBN in_IN units_NNS of_IN ten_CD years_NNS and_CC tumor_NN
          size_NN was_VBD grouped_VBN into_IN units_NNS of_IN ten_CD millimeters_NNS (_( one_CD
          centimeter_NN )_) ._. For_IN analyses_NNS of_IN ethnicity_NN as_IN a_DT predictor_NN of_IN
          treatment_NN selection_NN ,_, Caucasian_NNP was_VBD used_VBN as_IN the_DT control_NN
          group_NN and_CC indicator_NN variables_NNS for_IN all_DT other_JJ ethnic_JJ groups_NNS
          were_VBD created_VBN ._. Logistic_NNP regression_NN [_NN 28_CD ]_NN was_VBD used_VBN to_TO
          explore_VB the_DT influence_NN of_IN each_DT variable_NN on_IN the_DT use_NN of_IN BCS_NNP 
          vs_NNS ._. mastectomy_NN ._. First_LS ,_, we_PRP
          considered_VBD each_DT independent_JJ variable_NN by_IN itself_PRP in_IN a_DT model_NN
          and_CC then_RB we_PRP entered_VBD all_DT variables_NNS simultaneously_RB in_IN a_DT
          logistic_JJ regression_NN model_NN ._. Odds_NNS Ratios_NNP (_( OR_NNP )_) [_NN 29_CD ]_NN with_IN
          corresponding_JJ 95_CD %_NN Confidence_NNP Intervals_NNP (_( CI_NNP )_) were_VBD
          calculated_VBN to_TO measure_VB the_DT degree_NN of_IN influence_NN of_IN
          variables_NNS on_IN the_DT utilization_NN of_IN BCS_NNP 
          vs_NNS ._. mastectomy_NN ._.
        
      
      
        Results_NNS
        Based_VBN on_IN the_DT TNM_NNP stages_NNS ,_, we_PRP identified_VBD 722_CD women_NNS who_WP had_VBD
        stage_NN I_PRP ,_, IIA_NNP ,_, or_CC IIB_NNP breast_NN cancer_NN (_( 66_CD ._. 4_LS %_NN of_IN the_DT 1_CD ,_, 088_CD
        breast_NN cancer_NN cases_NNS in_IN the_DT linked_VBN data_NN set_VBN )_) ._. These_DT 722_CD
        cases_NNS represented_VBD 32_CD ._. 8_CD %_NN (_( 722_CD of_IN 2_CD ,_, 203_CD cases_NNS )_) of_IN all_DT early_JJ
        stage_NN breast_NN cancer_NN cases_NNS recorded_VBN in_IN the_DT HTR_NNP during_IN the_DT
        study_NN period_NN ._. Approximately_RB two-thirds_NNS of_IN the_DT women_NNS in_IN the_DT
        study_NN population_NN (_( Table_NNP 1_LS )_) were_VBD diagnosed_VBN in_IN stage_NN I_PRP of_IN the_DT
        disease_NN and_CC only_RB 24_CD %_NN and_CC 12_CD %_NN in_IN stage_NN IIA_NNP and_CC IIB_NNP ,_,
        respectively_RB ._. Approximately_RB 30_CD %_NN of_IN the_DT study_NN subjects_NNS were_VBD
        aged_VBN less_JJR than_IN 50_CD years_NNS ,_, close_RB to_TO half_NN were_VBD 50_CD to_TO 64_CD years_NNS
        old_JJ ,_, and_CC 21_CD %_NN were_VBD 65_CD years_NNS and_CC older_JJR ._. Three_CD out_IN of_IN four_CD
        women_NNS resided_VBN on_IN the_DT island_NN of_IN Oahu_NNP ._. Overall_RB ,_, 52_CD ._. 8_CD %_NN of_IN the_DT
        women_NNS had_VBD received_VBN BCS_NNP ._. Of_IN the_DT cases_NNS diagnosed_VBN at_IN stage_NN I_PRP ,_,
        57_CD %_NN of_IN the_DT women_NNS had_VBD received_VBN BCS_NNP and_CC 47_CD %_NN a_DT mastectomy_NN ._.
        This_DT decreased_VBD to_TO 50_CD %_NN for_IN stage_NN IIA_NNP and_CC to_TO 34_CD %_NN for_IN stage_NN
        IIB_NNP ._. Among_IN women_NNS ,_, 65_CD years_NNS and_CC older_JJR ,_, 56_CD %_NN had_VBD BCS_NNP ,_, compared_VBN
        to_TO 50_CD %_NN of_IN those_DT under_IN 50_CD years_NNS of_IN age_NN and_CC 53_CD %_NN of_IN the_DT 50_CD -_: 64_CD
        year_NN old_JJ women_NNS ._. While_IN 56_CD %_NN of_IN women_NNS on_IN Oahu_NNP underwent_VBD BCS_NNP ,_,
        only_RB 43_CD %_NN of_IN the_DT women_NNS residing_VBG on_IN the_DT outer_JJ islands_NNS
        received_VBD BCS_NNP ._. We_PRP observed_VBD no_DT statistically_RB significant_JJ
        differences_NNS between_IN the_DT BCS_NNP and_CC mastectomy_NN group_NN in_IN terms_NNS
        of_IN ethnicity_NN ,_, comorbidity_NN count_NN ,_, menopausal_NN status_NN ,_, marital_JJ
        status_NN ,_, and_CC insurance_NN plan_NN ._. We_PRP found_VBD very_RB high_JJ agreement_NN
        between_IN HTR_NNP data_NNS and_CC claims_NNS data_NNS in_IN identifying_VBG BCS_NNP [_NN κ_NN =_SYM
        0_CD ._. 91_CD (_( 95_CD %_NN CI_NNP 0_CD ._. 88_CD ,_, 0_CD ._. 94_CD )_) ]_NN ,_, only_RB 32_CD women_NNS were_VBD
        misclassified_VBN ._. For_IN the_DT majority_NN of_IN women_NNS who_WP received_VBD BCS_NNP
        (_( 92_CD ._. 1_LS %_NN )_) ,_, the_DT lumpectomy_NN was_VBD followed_VBN by_IN radiation_NN therapy_NN ._.
        Additional_JJ chemotherapy_NN was_VBD given_VBN to_TO 34_CD ._. 1_LS %_NN and_CC 42_CD ._. 5_LS %_NN of_IN the_DT
        women_NNS who_WP had_VBD a_DT lumpectomy_NN or_CC a_DT mastectomy_NN ,_,
        respectively_RB ._.
        In_IN the_DT univariate_NN models_NNS (_( Table_NNP 1_LS )_) ,_, we_PRP found_VBD that_DT tumor_NN
        size_NN and_CC grade_NN ,_, island_NN of_IN residence_NN ,_, age_NN ,_, and_CC stage_NN at_IN
        diagnosis_NN were_VBD predictors_NNS of_IN breast_NN cancer_NN treatment_NN ._. Women_NNP
        residing_VBG on_IN Oahu_NNP were_VBD considerably_RB more_RBR likely_JJ to_TO have_VB BCS_NNP
        than_IN women_NNS living_VBG on_IN all_DT other_JJ islands_NNS in_IN the_DT state_NN ._. For_IN
        each_DT one-centimeter_JJ increase_NN in_IN tumor_NN size_NN ,_, there_EX was_VBD a_DT 3_CD %_NN
        lesser_JJR chance_NN of_IN undergoing_VBG BCS_NNP ._. Since_IN size_NN of_IN tumor_NN
        correlates_NNS to_TO breast_NN cancer_NN stage_NN ,_, this_DT also_RB decreased_VBN the_DT
        likelihood_NN for_IN women_NNS in_IN stage_NN IIA_NNP and_CC IIB_NNP to_TO receive_VB BCS_NNP ._.
        Women_NNS with_IN well-differentiated_JJ tumor_NN grades_NNS were_VBD 50_CD %_NN more_RBR
        likely_JJ to_TO undergo_VB BCS_NNP as_IN compared_VBN to_TO women_NNS with_IN all_DT other_JJ
        grades_NNS ._. We_PRP found_VBD that_IN for_IN each_DT ten-year_JJ increment_NN in_IN age_NN ,_,
        the_DT chances_NNS of_IN having_VBG BCS_NNP increased_VBN by_IN 1_CD %_NN ._. We_PRP also_RB observed_VBD
        that_IN average_JJ tumor_NN size_NN was_VBD inversely_RB related_VBN to_TO age_NN ._. Mean_VB
        tumor_NN sizes_NNS (_( in_IN cm_NN )_) with_IN standard_JJ deviations_NNS were_VBD 1_CD ._. 82_CD ±_NN
        1_CD ._. 1_CD ,_, 1_CD ._. 59_CD ±_NN 1_CD ._. 2_CD ,_, 1_CD ._. 39_CD ±_NN 0_CD ._. 94_CD for_IN women_NNS younger_JJR than_IN 50_CD
        years_NNS ,_, 50_CD to_TO 64_CD years_NNS ,_, and_CC 65_CD years_NNS and_CC older_JJR ,_,
        respectively_RB ._. Therefore_RB ,_, the_DT smaller_JJR tumor_NN sizes_NNS may_MD
        account_VB for_IN the_DT greater_JJR likelihood_NN of_IN BCS_NNP among_IN older_JJR
        women_NNS ._.
        In_IN a_DT combined_VBN model_NN with_IN all_DT independent_JJ variables_NNS in_IN a_DT
        logistic_JJ regression_NN ,_, island_NN of_IN residence_NN remained_VBD the_DT only_RB
        significant_JJ predictor_NN of_IN BCS_NNP in_IN this_DT population_NN ._. Women_NNP
        living_VBG on_IN Oahu_NNP were_VBD 67_CD %_NN more_RBR likely_JJ to_TO have_VB BCS_NNP than_IN women_NNS
        on_IN the_DT outer_JJ islands_NNS ._. Although_IN all_DT other_JJ variables_NNS lost_VBD
        their_PRP$ statistical_JJ significance_NN ,_, associations_NNS for_IN age_NN ,_, TNM_NNP
        stage_NN ,_, tumor_NN size_NN ,_, and_CC tumor_NN grade_NN remained_VBD similar_JJ in_IN
        magnitude_NN as_IN in_IN the_DT univariate_NN models_NNS ._. Although_IN none_NN of_IN the_DT
        ethnicity_NN variables_NNS was_VBD significant_JJ ,_, it_PRP appeared_VBD that_IN
        Filipino_NNP women_NNS were_VBD less_RBR likely_JJ to_TO receive_VB BCS_NNP than_IN women_NNS
        from_IN all_DT other_JJ groups_NNS ._. Residence_NNP on_IN outer_JJ islands_NNS did_VBD not_RB
        explain_VB this_DT observation_NN ._. Women_NNS with_IN a_DT TNM_NNP stage_NN of_IN IIB_NNP
        were_VBD still_RB 40_CD %_NN less_RBR likely_JJ to_TO receive_VB BCS_NNP than_IN women_NNS
        diagnosed_VBN at_IN stage_NN I_PRP ,_, but_CC the_DT relation_NN lost_VBD its_PRP$ statistical_JJ
        significance_NN due_JJ to_TO the_DT small_JJ number_NN of_IN cases_NNS ._. Menopausal_NNP
        or_CC marital_JJ status_NN ,_, type_NN of_IN health_NN plan_NN ,_, or_CC the_DT number_NN of_IN
        comorbidities_NNS were_VBD not_RB related_VBN to_TO the_DT type_NN of_IN surgery_NN ._.
      
      
        Discussion_NNP
        The_DT place_NN of_IN residence_NN at_IN the_DT time_NN of_IN diagnosis_NN was_VBD the_DT
        most_RBS important_JJ predictor_NN for_IN receiving_VBG BCS_NNP in_IN this_DT dataset_NN
        of_IN health_NN plan_NN members_NNS ._. Women_NNS with_IN early_JJ stage_NN breast_NN
        cancer_NN living_VBG on_IN Oahu_NNP were_VBD 70_CD %_NN more_RBR likely_JJ to_TO have_VB BCS_NNP than_IN
        women_NNS living_VBG on_IN outer_JJ islands_NNS ._. Age_NNP at_IN diagnosis_NN and_CC tumor_NN
        size_NN were_VBD also_RB related_VBN to_TO breast_NN cancer_NN treatment_NN although_IN
        they_PRP were_VBD not_RB statistically_RB significant_JJ in_IN the_DT combined_VBN
        model_NN ._. Contrary_JJ to_TO our_PRP$ expectation_NN and_CC a_DT previous_JJ
        publication_NN [_NN 13_CD ]_NN ,_, the_DT number_NN of_IN comorbid_NN conditions_NNS did_VBD
        not_RB effect_VB treatment_NN in_IN this_DT analysis_NN ._. The_DT importance_NN of_IN
        geographic_JJ location_NN can_MD be_VB explained_VBN by_IN the_DT availability_NN of_IN
        radiation_NN facilities_NNS on_IN the_DT different_JJ Hawaiian_JJ Islands_NNP ._.
        Whereas_IN on_IN Oahu_NNP treatment_NN facilities_NNS can_MD be_VB reached_VBN within_IN
        one_CD hour_NN ,_, distances_NNS on_IN the_DT outer_JJ islands_NNS are_VBP much_JJ farther_RBR ._.
        Only_RB the_DT Island_NNP of_IN Hawaii_NNP and_CC Maui_NNP have_VBP a_DT radiation_NN
        facility_NN ,_, but_CC they_PRP are_VBP hard_JJ to_TO reach_VB from_IN many_JJ parts_NNS of_IN the_DT
        islands_NNS ._. Women_NNP residing_VBG on_IN Kauai_NNP ,_, Molokai_NNP ,_, and_CC Lanai_NNP have_VBP
        to_TO fly_VB to_TO Honolulu_NNP daily_JJ to_TO receive_VB the_DT course_NN of_IN treatment_NN
        or_CC they_PRP have_VBP to_TO remain_VB there_RB temporarily_RB ._. Because_IN this_DT may_MD
        be_VB not_RB be_VB economically_RB feasible_JJ for_IN some_DT women_NNS ,_, as_RB well_RB as_RB
        physically_RB and_CC psychologically_RB challenging_VBG ,_, it_PRP is_VBZ possible_JJ
        that_IN many_JJ women_NNS choose_VBP to_TO undergo_VB a_DT mastectomy_NN instead_RB ._.
        Alternatively_RB ,_, patients_NNS and_CC physicians_NNS in_IN rural_JJ areas_NNS may_MD
        favor_VB mastectomy_NN because_IN of_IN differences_NNS in_IN education_NN or_CC
        cultural_JJ attitudes_NNS toward_IN medical_JJ advances_NNS ._. We_PRP do_VBP not_RB have_VB
        information_NN to_TO explain_VB why_WRB a_DT small_JJ proportion_NN of_IN women_NNS who_WP
        underwent_VBD BCS_NNP (_( 6_CD ._. 9_CD %_NN )_) did_VBD not_RB receive_VB radiation_NN ._. However_RB ,_,
        compared_VBN to_TO other_JJ reports_NNS [_NN 13_CD 30_CD 31_CD ]_NN ,_, the_DT proportion_NN of_IN
        women_NNS who_WP received_VBD radiation_NN is_VBZ very_RB high_JJ ._. An_DT interview_NN
        study_NN with_IN cancer_NN patients_NNS [_NN 32_CD ]_NN showed_VBD that_IN some_DT patients_NNS
        decide_VBP against_IN their_PRP$ physicians_NNS '_POS recommendation_NN for_IN
        radiation_NN because_IN they_PRP fear_VBP the_DT treatment_NN or_CC hold_VB certain_JJ
        beliefs_NNS about_IN cancer_NN ._. For_IN other_JJ patients_NNS ,_, radiation_NN may_MD
        have_VB been_VBN contraindicated_JJ due_NN to_TO comorbid_NN conditions_NNS ._.
        In_IN 1994_CD ,_, a_DT national_JJ BCS_NNP rate_NN of_IN 42_CD ._. 6_CD %_NN was_VBD reported_VBN [_NN 33_CD
        ]_NN with_IN a_DT rate_NN of_IN 46_CD ._. 7_CD %_NN for_IN the_DT Pacific_NNP region_NN (_( Hawaii_NNP ,_,
        California_NNP ,_, Alaska_NNP ,_, Washington_NNP ,_, and_CC Oregon_NNP )_) ._. Our_PRP$ results_NNS
        for_IN 1995_CD to_TO 1998_CD indicate_VBP a_DT slightly_RB higher_JJR rate_NN for_IN Hawaii_NNP
        (_( 52_CD ._. 8_CD %_NN )_) ._. Geographic_NNP differences_NNS in_IN BCS_NNP use_NN have_VBP repeatedly_RB
        been_VBN described_VBN in_IN the_DT literature_NN ._. In_IN western_JJ Washington_NNP [_NN
        34_CD ]_NN ,_, women_NNS residing_VBG outside_IN the_DT Seattle_NNP area_NN were_VBD less_RBR
        likely_JJ to_TO have_VB BCS_NNP than_IN women_NNS residing_VBG inside_IN the_DT county_NN ,_,
        in_IN particular_JJ if_IN radiation_NN therapy_NN facilities_NNS were_VBD not_RB
        available_JJ in_IN their_PRP$ county_NN ._. Comparing_VBG rates_NNS across_IN the_DT
        country_NN showed_VBD that_IN BCS_NNP was_VBD much_RB more_RBR common_JJ in_IN the_DT
        Northeast_NNP than_IN in_IN the_DT South_NNP [_NN 33_CD ]_NN ._. Low_NNP BCS_NNP rates_NNS were_VBD
        also_RB found_VBN in_IN rural_JJ areas_NNS ,_, such_JJ as_IN North_NNP and_CC South_JJ Carolina_NNP
        [_NN 10_CD ]_NN ,_, Minnesota_NNP [_NN 35_CD ]_NN ,_, and_CC the_DT Southwest_NNP [_NN 36_CD ]_NN ._. An_DT
        analysis_NN of_IN 1991_CD -_: 1992_CD SEER_NNP data_NNS [_NN 37_CD ]_NN demonstrated_VBD a_DT
        strong_JJ association_NN between_IN BCS_NNP and_CC distance_NN to_TO the_DT next_JJ
        radiotherapy_NN facility_NN ._. The_DT likelihood_NN of_IN undergoing_VBG BCS_NNP was_VBD
        50_CD %_NN lower_JJR among_IN women_NNS living_VBG more_JJR than_IN 15_CD miles_NNS from_IN the_DT
        next_JJ radiotherapy_NN facility_NN ._.
        In_IN contrast_NN to_TO our_PRP$ results_NNS ,_, a_DT number_NN of_IN studies_NNS have_VBP
        shown_VBN that_IN the_DT likelihood_NN of_IN BCS_NNP decreases_NNS with_IN increasing_VBG
        age_NN [_NN 11_CD 30_CD 33_CD ]_NN ,_, possibly_RB due_JJ to_TO less_JJR concern_NN about_IN
        cosmetic_JJ results_NNS ._. Because_IN of_IN the_DT relatively_RB small_JJ
        proportion_NN (_( 21_CD %_NN )_) of_IN women_NNS 65_CD years_NNS and_CC older_JJR and_CC the_DT fact_NN
        that_IN the_DT women_NNS 65_CD years_NNS and_CC older_JJR in_IN our_PRP$ study_NN had_VBD a_DT health_NN
        plan_NN other_JJ than_IN Medicare_NNP ,_, they_PRP were_VBD not_RB directly_RB comparable_JJ
        to_TO the_DT populations_NNS in_IN the_DT published_VBN literature_NN ._. Therefore_RB ,_,
        our_PRP$ ability_NN to_TO observe_VB an_DT effect_NN among_IN older_JJR women_NNS was_VBD
        limited_JJ ._. In_IN particular_JJ ,_, we_PRP were_VBD not_RB able_JJ to_TO examine_VB the_DT
        treatment_NN of_IN women_NNS 80_CD years_NNS and_CC older_JJR who_WP have_VBP been_VBN
        described_VBN as_IN receiving_VBG more_JJR BCS_NNP than_IN women_NNS age_VBP 65_CD to_TO 79_CD
        years_NNS [_NN 13_CD ]_NN ._. Our_PRP$ findings_NNS of_IN lower_JJR BCS_NNP in_IN smaller_JJR and_CC
        well_RB differentiated_JJ tumors_NNS agree_VBP with_IN previous_JJ studies_NNS [_NN 33_CD
        ]_NN ,_, but_CC the_DT absence_NN of_IN an_DT effect_NN of_IN comorbid_NN conditions_NNS
        disagrees_VBZ with_IN a_DT study_NN in_IN older_JJR women_NNS [_NN 13_CD ]_NN that_WDT showed_VBD a_DT
        higher_JJR rate_NN of_IN BCS_NNP in_IN women_NNS with_IN comorbidities_NNS ._. Type_NNP of_IN
        health_NN plan_NN did_VBD not_RB predict_VB type_NN of_IN treatment_NN in_IN our_PRP$ study_NN
        probably_RB because_IN the_DT majority_NN of_IN women_NNS in_IN this_DT data_NNS set_VBN had_VBD
        a_DT FFS_NNP plan_NN ._. In_IN previous_JJ analyses_NNS with_IN a_DT larger_JJR variety_NN of_IN
        health_NN plans_NNS ,_, HMO_NNP members_NNS were_VBD considerably_RB more_RBR likely_JJ to_TO
        receive_VB BCS_NNP in_IN San_NNP Francisco_NNP and_CC in_IN Seattle_NNP [_NN 19_CD ]_NN ._.
        Medicare_NNP and_CC Medicaid_NNP patients_NNS received_VBD more_JJR BCS_NNP in_IN a_DT North_NNP
        Carolina_NNP hospital_NN [_NN 7_CD ]_NN ._. However_RB ,_, a_DT study_NN using_VBG
        administrative_JJ data_NNS [_NN 38_CD ]_NN described_VBD lower_JJR BCS_NNP use_NN among_IN
        Medicaid_NNP patients_NNS and_CC treatment_NN was_VBD similar_JJ by_IN health_NN plan_NN
        [_NN 39_CD ]_NN in_IN Northern_NNP California_NNP ._.
        Our_PRP$ study_NN had_VBD several_JJ limitations_NNS ,_, including_VBG the_DT
        possibility_NN of_IN incomplete_JJ claims_NNS histories_NNS if_IN patients_NNS
        changed_VBD health_NN plans_NNS during_IN the_DT course_NN of_IN treatment_NN ,_, but_CC
        the_DT high_JJ agreement_NN with_IN HTR_NNP information_NN indicates_VBZ that_IN the_DT
        validity_NN of_IN insurance_NN claims_NNS information_NN was_VBD high_JJ ._.
        Continuing_VBG efforts_NNS by_IN the_DT health_NN plan_NN through_IN feedback_NN
        loops_NNS has_VBZ improved_VBN diagnostic_JJ coding_VBG [_NN 40_CD ]_NN in_IN Hawaii_NNP ,_, but_CC
        as_IN documented_VBN for_IN Medicare_NNP claims_VBZ ,_, problems_NNS remain_VBP [_NN 41_CD ]_NN ._.
        As_IN discussed_VBN above_IN ,_, our_PRP$ study_NN sample_NN of_IN breast_NN cancer_NN
        patients_NNS does_VBZ not_RB represent_VB the_DT population_NN of_IN the_DT state_NN ,_,
        excluding_VBG in_IN particular_JJ Medicare_NNP and_CC Medicaid_NNP recipients_NNS ,_,
        members_NNS of_IN a_DT typical_JJ HMO_NNP ,_, and_CC the_DT relatively_RB small_JJ number_NN
        of_IN uninsured_JJ patients_NNS ._. The_DT exclusion_NN of_IN Medicare_NNP claims_VBZ
        lead_VBP to_TO a_DT younger_JJR population_NN ,_, whereas_IN the_DT lack_NN of_IN Medicaid_NNP
        claims_VBZ biased_VBN the_DT cases_NNS toward_IN a_DT higher_JJR socioeconomic_JJ
        status_NN ._. On_IN the_DT other_JJ hand_NN ,_, the_DT study_NN population_NN represented_VBD
        the_DT population_NN quite_RB well_RB in_IN terms_NNS of_IN ethnicity_NN (_( Hawaii_NNP
        Department_NNP of_IN Business_NNP 1998_CD 1705_CD /_NN id_NN )_) ._. Because_IN our_PRP$ data_NNS set_VBN
        included_VBD 42_CD ._. 4_LS %_NN of_IN all_DT breast_NN cancer_NN cases_NNS under_IN 65_CD years_NNS
        diagnosed_VBN during_IN the_DT study_NN period_NN ,_, the_DT results_NNS represents_VBZ
        this_DT population_NN much_RB better_JJR than_IN the_DT population_NN of_IN older_JJR
        women_NNS ._. Also_RB ,_, we_PRP were_VBD unable_JJ to_TO measure_VB some_DT factors_NNS that_WDT
        have_VBP been_VBN found_VBN to_TO be_VB important_JJ in_IN other_JJ reports_NNS ,_, in_IN
        particular_JJ ,_, influence_NN of_IN physician_NN age_NN [_NN 11_CD ]_NN ,_, physician_NN
        specialty_NN [_NN 42_CD ]_NN ,_, type_NN of_IN hospital_NN (_( teaching_NN hospitals_NNS and_CC
        hospitals_NNS with_IN radiation_NN facilities_NNS ,_, private_JJ ,_, county_NN and_CC
        public_JJ )_) [_NN 36_CD 38_CD 39_CD 43_CD ]_NN ,_, socio-economic_JJ status_NN and_CC
        education_NN [_NN 42_CD ]_NN ,_, tumor-breast_JJ ratio_NN and_CC the_DT expected_VBN
        cosmetic_JJ results_NNS [_NN 7_CD 9_CD ]_NN ,_, physician_NN /_NN patient_NN interactions_NNS
        before_IN surgery_NN [_NN 42_CD ]_NN ,_, and_CC psychological_JJ factors_NNS ,_, such_JJ as_IN
        fear_NN of_IN radiation_NN or_CC cancer_NN [_NN 9_CD ]_NN ._. The_DT strengths_NNS of_IN using_VBG
        of_IN insurance_NN claims_VBZ data_NNS for_IN this_DT analysis_NN were_VBD twofold_NN ._.
        First_LS ,_, we_PRP had_VBD more_RBR detailed_JJ treatment_NN information_NN available_JJ
        than_IN collected_VBN by_IN the_DT tumor_NN registry_NN ._. Second_JJ ,_, the_DT
        diagnostic_JJ codes_NNS in_IN the_DT claims_NNS data_NN allowed_VBD us_PRP to_TO estimate_VB
        the_DT number_NN of_IN comorbid_NN conditions_NNS before_IN the_DT cancer_NN
        diagnosis_NN ._.
        The_DT results_NNS of_IN this_DT pilot_NN study_NN combining_VBG tumor_NN registry_NN
        and_CC insurance_NN claims_VBZ data_NNS raises_VBZ an_DT important_JJ issue_NN for_IN
        cancer_NN practice_NN in_IN the_DT State_NNP of_IN Hawaii_NNP and_CC elsewhere_RB ._.
        Health_NN care_NN providers_NNS and_CC insurance_NN plans_NNS need_VBP to_TO work_VB with_IN
        other_JJ agencies_NNS to_TO develop_VB viable_JJ solutions_NNS to_TO facilitate_VB
        access_NN to_TO radiation_NN facilities_NNS for_IN women_NNS residing_VBG in_IN remote_JJ
        locations_NNS ,_, such_JJ as_IN islands_NNS with_IN no_DT radiation_NN facility_NN ._.
        Attitudes_NNS of_IN patients_NNS and_CC physicians_NNS living_VBG in_IN rural_JJ areas_NNS
        may_MD be_VB important_JJ in_IN the_DT choice_NN of_IN treatment_NN ,_, but_CC could_MD not_RB
        be_VB investigated_VBN in_IN this_DT project_NN ._. Future_JJ research_NN that_WDT
        includes_VBZ interviews_NNS with_IN patients_NNS and_CC physicians_NNS may_MD
        investigate_VB attitudes_NNS toward_IN certain_JJ types_NNS of_IN treatment_NN and_CC
        identify_VB additional_JJ barriers_NNS to_TO BCS_NNP ,_, such_JJ as_IN psychological_JJ
        problems_NNS ._. In_IN order_NN to_TO understand_VB how_WRB treatment_NN decisions_NNS
        were_VBD made_VBN in_IN practice_NN ,_, qualitative_JJ information_NN from_IN
        physicians_NNS and_CC breast_NN cancer_NN patients_NNS should_MD be_VB collected_VBN
        and_CC examined_VBN in_IN detail_NN ._. Further_RB validation_NN of_IN treatment_NN and_CC
        comorbidity_NN from_IN insurance_NN claims_VBZ data_NNS would_MD strengthen_VB
        this_DT type_NN of_IN research_NN in_IN the_DT future_NN ._. The_DT inclusion_NN of_IN a_DT
        larger_JJR proportion_NN of_IN breast_NN cancer_NN cases_NNS is_VBZ needed_VBN to_TO
        establish_VB the_DT validity_NN of_IN our_PRP$ findings_NNS for_IN the_DT population_NN
        at-large_JJ ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
    
  
